Vaxart Inc expected to post a loss of 10 cents a share - Earnings Preview
18/03/2025 20:12
Vaxart Inc VXRT.OQ VXRT.O is expected to show a rise in quarterly revenue when it reports results on March 20 for the period ending December 31 2024 The South San Francisco California-based company is expected to report a 540.0% increase in revenue to $20.767 million from $3.25 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data. LSEG's mean analyst estimate for Vaxart Inc is for a loss of 10 cents per share. The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Vaxart Inc is $4.00, above its last closing price of $0.58. Previous quarterly performance (using preferred earnings measure in US dollars).
| QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
| Sep. 30 2024 | -0.11 | -0.10 | -0.06 | Beat | 40 |
| Jun. 30 2024 | 0.01 | -0.03 | -0.09 | Missed | -237.5 |
| Mar. 31 2024 | -0.14 | -0.14 | -0.14 | Met | 0 |
| Dec. 31 2023 | -0.16 | -0.14 | -0.12 | Beat | 17.2 |
| Sep. 30 2023 | -0.18 | -0.18 | -0.11 | Beat | 37.7 |
| Jun. 30 2023 | -0.18 | -0.18 | -0.16 | Beat | 11.1 |
| Mar. 31 2023 | -0.18 | -0.19 | -0.19 | Met | -1.8 |
| Dec. 31 2022 | -0.22 | -0.23 | -0.18 | Beat | 20.9 |
Recent news on Vaxart
See all newsBrief: Vaxart Expands Intellectual Property Portfolio With European Patent Protecting Proprietary Norovirus Vaccine Technology
Vaxart Q2 revenue falls on lower government contract income
Brief: Vaxart Q2 Net Income USD -13.494 Million
Brief: Vaxart Enters Cooperation Agreement With Stockholder Group And Announces Board And Corporate Governance Enhancements
Vaxart Q1 revenue more than doubles on government contracts